SLC5A2 and type 2 diabetes mellitus: Sodium glucose cotransporter-2 (SGLT-2) inhibitors, including canagliflozin, empagliflozin, and dapagliflozin, are the newest antihyperglycemic agents approved for treatment of type 2 diabetes.